Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

Similar articles for PubMed (Select 15342808)

1.

Management of cutaneous melanoma.

Tsao H, Atkins MB, Sober AJ.

N Engl J Med. 2004 Sep 2;351(10):998-1012. Review. No abstract available. Erratum in: N Engl J Med. 2004 Dec 2;351(23):2461.

PMID:
15342808
2.

Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.

Bajetta E.

Nat Clin Pract Oncol. 2008 Jan;5(1):4-5. Epub 2007 Nov 27. No abstract available.

PMID:
18043604
3.

The role of adjuvant interferon in high risk melanoma patients.

[No authors listed]

Dermatol Surg. 2000 Jun;26(6):607-8. No abstract available.

PMID:
10848951
4.

Duration of high-dose interferon alpha-2b regimen for resected high-risk melanoma.

Agarwala SS, Gray RJ, Wong MK.

J Clin Oncol. 2009 Sep 1;27(25):e82-3; author reply e84. doi: 10.1200/JCO.2009.23.0334. Epub 2009 Jul 27. No abstract available.

5.

Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.

Bouwhuis MG, Suciu S, Testori A, Kruit WH, Sal├Ęs F, Patel P, Punt CJ, Santinami M, Spatz A, Ten Hagen TL, Eggermont AM.

J Clin Oncol. 2010 May 10;28(14):2460-6. doi: 10.1200/JCO.2009.24.6264. Epub 2010 Apr 12.

6.

Update on the role of adjuvant interferon for high risk melanoma.

Agarwala SS, Kirkwood JM.

Forum (Genova). 2000 Jul-Sep;10(3):230-9. Review.

PMID:
11007931
7.

Malignant melanoma: non-metastatic.

Crosby D, Crosby T, Mason M.

Clin Evid. 2002 Jun;(7):1519-29. Review. No abstract available. Update in: Clin Evid. 2003 Jun;(9):1842-53.

PMID:
12230768
8.

Malignant melanoma and adjuvant alpha interferon-2b for patients at high risk of relapse.

Gale DM, Kiley KE.

Clin J Oncol Nurs. 1998 Jan;2(1):5-10. Review.

PMID:
9481250
9.
10.

Adjuvant interferon for melanoma.

Wheatley K, Ives N.

Ann Oncol. 2002 Aug;13(8):1319-20; author reply 1320. No abstract available.

11.

Adjuvant interferon in the treatment of melanoma.

Kirkwood JM.

Br J Cancer. 2000 May;82(10):1755-6. No abstract available.

12.

Comment on "Perhaps not everyone knows that...", (Ann Oncol 2001; 12: 1186).

Sulkes A, Schachter J.

Ann Oncol. 2002 Apr;13(4):637. No abstract available.

13.

High-dose adjuvant interferon therapy for melanoma.

Licata AG.

Dermatol Nurs. 1998 Oct;10(5):334-6.

PMID:
9873271
14.

Quality of life in patients receiving high-dose interferon alfa-2b after resected high-risk melanoma.

Mohr P, Hauschild A, Trefzer U, Weichenthal M.

J Clin Oncol. 2009 Aug 20;27(24):e70; author reply e71. doi: 10.1200/JCO.2009.23.3874. Epub 2009 Jul 20. No abstract available.

15.

The adjuvant treatment of malignant melanoma.

Reintgen D, Kirkwood J.

J Fla Med Assoc. 1997 Mar;84(3):147-52.

PMID:
9143164
16.

How does interferon work? Does it even matter?

Sondak VK.

Cancer. 2002 Sep 1;95(5):947-9. No abstract available.

17.

Primary cutaneous melanomas seen as inflamed pigmented lesions in patients undergoing adjuvant interferon treatment: a possible diagnostic clue for physicians.

Hu S, Kim CC, Jessup C, Phung TL, Curiel-Lewandrowski C.

Arch Dermatol. 2009 May;145(5):565-8. doi: 10.1001/archdermatol.2009.38.

PMID:
19451501
18.

Interferon adjuvant therapy of melanoma.

Kirkwood JM, Wazer D, Rosenstein M.

Cancer. 1997 May 1;79(9):1843-6. No abstract available.

PMID:
9129006
19.

Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study).

Fusi A, Collette S, Busse A, Suciu S, Rietz A, Santinami M, Kruit WH, Testori A, Punt CJ, Dalgleish AG, Spatz A, Eggermont AM, Keilholz U.

Eur J Cancer. 2009 Dec;45(18):3189-97. doi: 10.1016/j.ejca.2009.09.004. Epub 2009 Sep 28.

PMID:
19793643
20.

Topical imiquimod in the treatment of metastatic melanoma to skin.

Wolf IH, Smolle J, Binder B, Cerroni L, Richtig E, Kerl H.

Arch Dermatol. 2003 Mar;139(3):273-6. No abstract available.

PMID:
12622616
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk